Active — Not RecruitingPhase 2

Osimertinib In EGFR Mutant Lung Cancer

United States30 participantsStarted 2018-08-13

Plain-language summary

This research study is studying a targeted therapy as a possible treatment for Non-Small Cell Lung Cancer (NSCLC) with an EGFR mutation. The names of the study drug involved in this study is: \- Osimertinib (Tagrisso)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓-Note: recurrent stage IV disease initially diagnosed at an earlier stage is considered eligible, provided prior treatment criteria is met.
✓-Note: Cytology specimen may be acceptable for baseline NGS if tumor cellular content is sufficient and following PI approval. If there is no cytology specimen or tissue sample available for NGS, plasma-based NGS may be acceptable for enrollment following discussion with PI.

What they're measuring

Mechanisms of resistance to Osimertinib

Timeframe: 4 Months

Trial details

NCT IDNCT03586453

SponsorDana-Farber Cancer Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-02-28

View on ClinicalTrials.gov More Carcinoma, Non-Small-Cell Lung trials